Dergiler / Kıbrıs Türk Psikiyatri ve Psikoloji Dergisi / 2020 / Cilt: 2 - Sayı: 1

Risperidone and Hepatotoxicity in Children and Adolescent: A Literature Review

Sayfa
54–58
Yayın Tarihi
2020-04-04
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

However, more comprehensive studies investigating risperidone-associated hepatic adverse effects should be performed to reach a definitive outcome.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Risperidone is a second generation anti-psychotic drug that is commonly preferred in the treatment of schizophrenia, attention deficit hyperactivity disorder and bipolar disorders.
📊
Temel Bulgular & Veri:We performed literature search via electronic databases (PubMed, Embase and the Cochrane Library) in August 2019.
💡
Sonuç & Katkı:However, more comprehensive studies investigating risperidone-associated hepatic adverse effects should be performed to reach a definitive outcome.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2019 Verileri
⚙️Değişkenler:Risperidone · liver function tests · reversibility

Özet

Risperidone is a second generation anti-psychotic drug that is commonly preferred in the treatment of schizophrenia, attention deficit hyperactivity disorder and bipolar disorders. Risperidone-associated hepatic adverse effects have long been investigated and continues to be unclear. In this review, our aim is to establish the possible hepatic adverse effects linked to risperidone treatment in children and adolescent in terms of severities and reversibility. We performed literature search via electronic databases (PubMed, Embase and the Cochrane Library) in August 2019. Risperidone treatment may lead to alterations in liver function test (LFT), mostly asymptomatic and reversible with the discontinuation or normalizes with time. Furthermore, there are few cases reporting risperidone-induced cholestatic hepatitis and immunoallergic hepatitis. Although exact mechanism of action of risperidone on liver remains unknown, there are growing evidences that link alterations of fatty acid biosynthesis to hepatic adverse effects. We recommend physicians to take basal LFT prior to risperidone treatment and monitor LFT during treatment. Additionally, physicians should be aware that most alterations at LFT associated with risperidone use are asymptomatic and reversible. However, more comprehensive studies investigating risperidone-associated hepatic adverse effects should be performed to reach a definitive outcome.

🔖

Bu Makaleye Atıf Yap

ÇÖPÜR, M., ÇÖPÜR, S. (2020). Risperidone and Hepatotoxicity in Children and Adolescent: A Literature Review. Kıbrıs Türk Psikiyatri ve Psikoloji Dergisi, Cilt: 2 - Sayı: 1, 54–58. https://ajindex.com/articles/785149

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

  1. Atasoy, N., Erdogan, A., Yalug, I., Öztürk, Ü., Konuk, N., Atik, L. (2007). A review of liver function tests during treatment with atypical antipsychotic drugs: A chart review study. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 31(6), 1255- 60. Auger, F., Patrick, D., Françoise, M., Nizard, M.F., Durieux, N., Bordet, R. (2014). Long-term risperidone treatment induces visceral adiposity associated with hepatic steatosis in mice: A magnetic resonance approach. Schizophrenia Research and Treatment, 11. Azirak, S., Bilgic, S., Tastemir, K., Güvenç, A.N., Kocaman, N., Özer, M.K. (2019). The protective effect of resveratrol against risperidone-induced liver damage through an action on fas gene expression. General Physiology and Biophysics, 38(3), 215-225.
  2. Baeza, I., Serna, E., Calvo-Escalona, R., Naranjo, M.J., Latorre, R.P., Martinenz-Cantarero, C.M. (2018). One-year prospective study of liver function tests in children and adolescents on second-generation antipsychotics: Is there a link with metabolic syndrome? Journal of Child and Adolescent Psychopharmacology, 28(7), 463-73.
  3. Cohen, L.J. (1994). Risperidone. The Journal of Human Pharmacology and Drug Therapy,14(3), 253-265.
  4. Copur, M., Erdogan, A. (2011). Risperidone rechallenge for marked liver function test abnormalities in an autistic child. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 5(3), 237-239.
  5. Cordeiro, Q., Elkis, H. (2007). Pancreatitis and cholestatic hepatitis induced by risperidone. Journal of Clinical Psychopharmacology, 21(5), 529-30.
  6. Eftekhari, A., Ahmad-Durieuxsian, E., Azarmi, Y., Parvizpur, A., Hamishehkar, H., Eghbal, M.A. (2016). In vitro/vivo studies towards mechanisms of risperidone-induced oxidative stress and the protective role of coenzyme q10 and n-acetylcysteine. Toxicology Mechanisms and Methods, 26(7), 520-528.
  7. Erdogan, A., Atasoy, N., Akkurt, H., Öztürk, D., Karaahmet, E., Yaluğ, İ. (2008). Risperidone and liver function tests in children and adolescents: A short-term prospective study. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 32(3), 849-57.
  8. Erdogan, A., Karaman, M., Ozdemir, E., Yurteri, N., Tufan, E.A., Turcer, A.M. (2010). Six months of treatment with risperidone may be associated with nonsignificant abnormalities of liver function tests in children and adolescents: A longitudinal, observational study from turkey. Journal of Child and Adolescent Psychopharmacology, 20(5), 407-13.
  9. Esposito, D., Brocvielle, H., Becquemont